Assessing the overuse of medicines

Social Science and Medicine

Volumn 131, Issue , 2015, Pages 199-206

  Busfield, Joan ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

Antibiotics; Antidepressants; Antihypertensives; Doctors' risk avoidance; Overuse of medicines; Pharmaceutical marketing; Pharmaceuticalisation; Rational use of medicines

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; NEUROLEPTIC AGENT; PLACEBO; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; ANTIINFECTIVE AGENT;

ANTIBIOTICS; ASSESSMENT METHOD; DRUG PRESCRIBING; HEALTH WORKER; MARKETING; PHARMACEUTICAL INDUSTRY;

ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BACTERIAL INFECTION; CEREBROVASCULAR ACCIDENT; COMMON COLD; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DROWSINESS; DRUG ABUSE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MISUSE; DRUG SAFETY; DRUG USE; HEADACHE; HEART INFARCTION; HUMAN; HYPERACTIVITY; INSOMNIA; NAUSEA; PATIENT CARE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOSIS; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SELF MEDICATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL INTERACTION; SUICIDAL IDEATION; SUICIDE; WORLD HEALTH ORGANIZATION; CLINICAL PRACTICE; DEFENSIVE MEDICINE; DRUG UTILIZATION; FORECASTING; MARKETING; TREATMENT OUTCOME; TRENDS;

ANTI-BACTERIAL AGENTS; ANTIHYPERTENSIVE AGENTS; DEFENSIVE MEDICINE; DRUG INDUSTRY; DRUG UTILIZATION; FORECASTING; HUMANS; MARKETING; PRACTICE PATTERNS, PHYSICIANS'; PRESCRIPTION DRUG OVERUSE; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 84925353392     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2014.10.061     Document Type: Article

References (70)

1. Abraham J. Pharmaceuticalization of society in context. Sociology 2010, 44:603-622.
2. Angell M. The Truth about the Drug Companies 2005, Random House, New York.
3. APA Diagnostic and Statistical Manual of Mental Disorders 1968, American Psychiatric Association, Washington. second ed.
4. APA Diagnostic and Statistical Manual of Mental Disorders 1980, American Psychiatric Association, Washington. third ed.
5. APA Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington. fourth ed.
6. APA Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Association, Washington. fifth ed.
7. Banerjee S. The Use of Antipsychotic Medication for People with Dementia 2009, Department of Health, London.
8. Bell S., Figert A. Medicalization and pharmaceuticalization at the crossroads: looking backward, sideways and forward. Soc. Sci. Med. 2012, 75:775-783.
9. Bounameaux H., Perrier A. Duration of anticoagulant therapy for venous thromboembolism. Hematology 2008, 1:252-258.
10. Brugha T.S., Bebbington P.E., MacCarthy B., et al. Antidepressants may not assist recovery in practice. Acta Psychiatr. Scand. 1992, 86:5-11.
11. Busfield J. Pills, power, people: sociological understandings of the pharmaceutical industry. Sociology 2006, 40:297-314.
12. Busfield J. Transforming misery into sickness: the genealogy of depression in the DSM. De-medicalizing Misery II: Society, Politics and the Mental Health Industry 2014, Palgrave Macmillan, London. E. Speed, J. Moncrieff, M. Rapley (Eds.).
13. Butler C.C., Rollnick S., Pill R., et al. Understanding the culture of prescribing: qualitative study of general practitioners' and patients' perceptions of antibiotics for sore throats. BMJ 1998, 317:637-642.
14. Care Quality Commission The Safer Management of Controlled Drugs: Annual Report 2012 2013, Care Quality Commission, London.
15. Centers for Disease Control and Prevention ADHD, Data and Statistics 2014, (accessed 11.07.14.). http://www.cdc.gov.ncbddd/adhd/data.html.
16. Cohen J.S. Dose discrepancies between the Physicians' Desk Reference and the medical literature and their possible role in the high incidence of dose-related adverse drug events. Arch. Intern. Med. 2001, 16:957-963.
17. Cohen D., McCubbin M., Collin J., Perodeau G. Medications as social phenomena. Health 2001, 5:441-469.
18. Conrad P. The Medicalization of Society 2007, John Hopkins Press, Balitmore.
19. Conrad P., Potter D. From hyperactive children to ADHD adults. Soc. Probl. 2000, 47:559-582.
20. Department of Health Prescriptions Dispensed in the Community Statistics for 1989 to 1999 2000, Department of Health, England, London.
21. Diao D., Wright J.M., Gueyffer F. Pharmacotherapy for Mild Hypertension (Review) 2012, Cochrane Library, 11.
22. Dumit J. Drugs for Life: How Pharmaceutical Companies Define Our Health 2012, Duke University Press, Durham, NC.
23. Gagnon M.-A., Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditure in the United States. PLoS Med. 2008, 5:e1.
24. Goldacre B. Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients 2012, Fourth Estate, London.
25. Goossens H., Ferech M., Veander Stichele R., et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005, 365:579-587.
26. Goossens H., Ferech M., Coenen S., et al. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European Countries. Clin. Infect. Dis. 2007, 44:1091-1095.
27. Greene J.A. Prescribing by Numbers: Drugs and the Definition of Disease 2007, John Hopkins University Press, Baltimore.
28. Haw C., Yorston G., Stubbs J. Guidelines on antipsychotics for dementia: are we losing our minds. Psychiatr. Bull. 2009, 33:57-60.
29. Health I.M.S. World Pharma Market Summary 2013, IMS Health, (February).
30. Health and Social Care Information Centre Prescriptions Dispensed in the Community: England 2002-12 2013, (London).
31. Healy D. The Anti-depressant Era 1997, Harvard University Press, Harvard.
32. Healy D. The Prozac Era 2004, New York University Press, New York.
33. Healy D. Pharmageddon 2012, University of California Press, Berkeley.
34. Hilmer S.N., Gnjidic D. The effects of polypharmacy in older adults. Discovery 2009, 85:86-88.
35. Horwitz A.V., Wakefield J.C. The Loss of Sadness 2007, Oxford University Press, New York.
36. Institute of Medicine Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease 2010, IOM, Washington.
37. Ioannidis J.P.A. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials. Philos. Ethics Humanit. Med. 2008, 3:14.
38. Jacobs B.I., Zhang Y., Schroek F.R., et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA 2013, 309:2587-2595.
39. Kirk S.A., Kutchins H. The Selling of the DSM 1992, Aldine, New York.
40. Kirsch I. The Emperor's New Drugs: Exploding the Antidepressant Myth 2009, Bodley Head, London.
41. Kirsch I., Brett J., Deacon T.B., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med. 2008, 2:e45.
42. Marchant I., Nony P., Boissel J-P, et al. The global risk approach should be better applied in French hypertensive patients. PLoS One 2011, 6:e17508.
43. Mayes R., Horwitz A.V. DSM-III and the revolution in the classification of mental illness. J.Hist. Behav. Sci. 2005, 41:249-267.
44. McIsaac W.J., Butler C.C. Does clinical error contribute to unnecessary antibiotic use?. Med. Decis. Mak. 2000, 20:33-38.
45. Moncrieff J. The Myth of the Chemical Cure, Revised Edition 2009, Palgrave, London.
46. Moncrieff J., Kirsch I. Efficacy of antidepressants in adults. BMJ 2005, 331:155-157.
47. Olfson M., Marcus S.C. National patterns in antidepressant medication treatment. Arch. Gen. Psychiatry 2009, 66:848-856.
48. Olfson M., Blanco C., Liu S.M., et al. National trends in the office-based treatment of children, adolescents and adults with antipsychotics. Arch. Gen. Psychiatry 2012, 69:1247-1256.
49. Pacher P., Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr. Pharm. Des. 2004, 10:2463-2475.
50. Public Health England English Surveillance Programme for Antimicrobial Utilisation and Resistance 2014, Public Health England, London.
51. Read J., Cartwright C., Gibson K. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Res. 2014, 216:67-73.
52. Reeves A., McKee M., Stuckler D. Economic suicides in the great recession in Europe and North America. Br. J. Psychiatry 2014, 10.11.92/bjp.bp.114.144766.
53. Scheff T.J. Decision rules, types of error, and their consequences in medical diagnosis. Behav. Sci. 1963, 8:97-107.
54. Scott J. Documentary Research 2006, Sage, London.
55. Sikich L., Fraizer J.A., McClellan, et al. Double-blind comparison for first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder. Am. J. Psychiatry 2008, 165:1420-1431.
56. Sun Q., Santoro M.S., Meng Q., et al. Pharmaceutical policy in China. Health Aff. 2008, 27:1042-1050.
57. Thoits P. Mechanisms linking social ties and support to physical and mental health. J.Health Soc. Behav. 2011, 52:145-146.
58. Towse A., Keiuffel E., Kettler H.E., Ridely D.N. Drugs and Vaccines for Developing Countries, London 2011, Office of Health Economics.
59. Turner E.H., Matthews A.M., Linardatos E., et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N.Engl. J. Med. 2008, 358:252-260.
60. Van Roosmalen M.S., Braspenning J.C.C., De Smet P.A.G., Grol R.P.T.M. Antibiotic prescribing in primary care. Qual. Saf. Health Care 2007, 16:105-109.
61. Viera A.J. Predisease: when does it make sense?. Am. J. Epidemiol. 2011, 33:122-134.
62. WHO The Rational Use of Drugs: Report of the Conference of Experts 1985, World Health Organisation, Geneva.
63. WHO WHO Policy Perspectives on Medicines - Promoting Rational Use of Medicines 2002, World Health Organisation, Geneva.
64. WHO The World Medicines Situation 2004, World Health Organisation, Geneva.
65. WHO The Conceptual Framework for the International Classification for Patient Safety: Technical Annex 2 2009, World Health Organisation, Geneva.
66. WHO The World Medicines Situation: Pharmaceutical Consumption 2011, World Health Organisation, Geneva.
67. WHO The World Medicines Situation: Rational Use of Medicines 2011, World Health Organisation, Geneva.
68. Williams S.J., Martin P., Gabe J. The pharmaceuticalisation of society? A framework for analysis. Sociol. Health Illn. 2009, 33:710-725.
69. World Bank 'Physicians (per 1,000 people) 2014, (accessed 04.07.14.). http://data.worldbank.org/indicator/SH.MED.PHYS.ZS.
70. Zhan S., Tang S., Guo Y. Drug prescribing in rural health facilities in China. Trop. Dr. 1998, 28:42-48.